v3.26.1
Condensed Consolidated Statements of Stockholders' Equity / (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Treasury Stock [Member]
Non controlling Interest [Member]
Begning Balance at Dec. 31, 2024 $ (192,641) $ 1 $ 1 $ 454,614 $ 6,317 $ (563,052) $ (90,522)  
Begning Balance (in shares) at Dec. 31, 2024   34,057 6,952          
Treasury Stock, Beginning Balance (in shares) at Dec. 31, 2024             1,716  
Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral 2,182     (5,353)     $ 7,535  
Treasury Stock transferred to Tranche B Investors for Tranche B Note deferral, Shares             (143)  
Treasury Stock paid for Gloperba Ex-U.S. License 366     (808)     $ 1,174  
Treasury Stock paid for Gloperba Ex-U.S. License, Shares             (22)  
Treasury Stock transferred to Oramed for the Oramed Note maturity extension 1,375     (3,523)     $ 4,898  
Treasury Stock transferred to Oramed for the Oramed Note maturity extension, Shares             (93)  
Stock-based compensation 3,314     3,314        
Other comprehensive income 0              
Net Income (Loss) (26,080)         (26,080)    
Ending Balance at Mar. 31, 2025 (211,484) $ 1 $ 1 448,244 6,317 (589,132) $ (76,915)  
Ending Balance (in shares) at Mar. 31, 2025   34,057 6,952          
Treasury Stock, Ending Balance (in shares) at Mar. 31, 2025             1,458  
Begning Balance at Dec. 31, 2025 $ (211,752) $ 1 $ 1 796,721 (5,803) (921,786) $ (76,915) $ (3,971)
Begning Balance (in shares) at Dec. 31, 2025   34,057 8,491          
Treasury Stock, Beginning Balance (in shares) at Dec. 31, 2025 1,458,263           1,458  
Stock dividend declared in 2024, and canceled in February 2026, (shares)   (5,000)            
Stock dividend declared in 2024, and canceled in February 2026   $ (1)   1        
Stockholders' Equity Beginning Balance at Dec. 31, 2025 $ (207,781)              
Acquisition of controlling interest in Vivasor 1,500             1,500
Vivasor - secondary purchase Three I Fund Agreement and Shah Agreement (1,050)     (1,050)        
Stock-based compensation 3,629     3,629        
Other comprehensive income (747)       (747)      
Net Income (Loss) (45,650)         (43,270)   (2,380)
Ending Balance at Mar. 31, 2026 $ (254,070) $ 0 $ 1 $ 799,301 $ (6,550) $ (965,056) $ (76,915) $ (4,851)
Ending Balance (in shares) at Mar. 31, 2026   29,057 8,491          
Treasury Stock, Ending Balance (in shares) at Mar. 31, 2026 1,458,263           1,458  
Stockholders' Equity Ending Balance at Mar. 31, 2026 $ (249,219)